3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Carcinoma, Non-Small-Cell Lung
148
Breast Neoplasms
117
Prostatic Neoplasms
62
Multiple Myeloma
57
Neoplasms
56
Lung Neoplasms
50
Neoplasm Metastasis
44
Parkinson Disease 4, Autosomal Dominant Lewy Body
36
Ovarian Neoplasms
36
Colorectal Neoplasms
35
Leukemia, Lymphocytic, Chronic, B-Cell
33
Carcinoma, Renal Cell
27
Recurrence
26
Leukemia, Myeloid, Acute
26
Urinary Bladder Neoplasms
25
Carcinoma, Hepatocellular
24
Small Cell Lung Carcinoma
23
Myasthenia Gravis
22
Triple Negative Breast Neoplasms
21
Endometrial Neoplasms
21
Squamous Cell Carcinoma of Head and Neck
20
Lymphoma, Large B-Cell, Diffuse
20
Lymphoma, Follicular
20
Melanoma
19
Nasopharyngeal Carcinoma
18
Fallopian Tube Neoplasms
18
Stomach Neoplasms
17
Non-Muscle Invasive Bladder Neoplasms
16
Brain Neoplasms
16
Pancreatic Neoplasms
15
Interventions
4-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Amyloid Neuropathies, Familial
×
90 days
×
Clear all
NCT05184088
2026-06-02
CArdiag
Lantheus Biosciences Ltd.
Phase 3
Completed
244 enrolled